New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
08:32 EDTGILDGilead's Sofosbuvir for hepatitis C meets primary endpoint in Phase 3 study
Gilead Sciences announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus infection who failed prior treatment. The study met its primary efficacy endpoint of superiority compared to a predefined historic control sustained virologic response rate of 25%. In FUSION, 50% of patients in the 12-week arm and 73% of patients in the 16-week arm achieved SVR12. “This study demonstrates that all-oral therapy with sofosbuvir provides significant efficacy among difficult-to-treat hepatitis C patients who could not be cured by prior regimens containing pegylated interferon and now have limited treatment options,” said Norbert Bischofberger, PhD, Executive Vice President of Research and Development and Chief Scientific Officer. “With positive results from all four Phase 3 trials now in hand, Gilead is on track to meet its goal of filing regulatory applications in the United States and Europe in the second quarter.”
News For GILD From The Last 14 Days
Check below for free stories on GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent GILD news | >>
September 8, 2014
08:48 EDTGILDGilead announces AMBITION study results in collaboration with Glaxo
Subscribe for More Information
September 5, 2014
16:45 EDTGILDMarket ends week little changed after mixed economic data
Subscribe for More Information
12:57 EDTGILDOn The Fly: Midday Wrap
Subscribe for More Information
12:04 EDTGILDGilead shares defended on today's weakness at Deutsche Bank
12:02 EDTGILDStocks with call strike movement; DAL GILD
Subscribe for More Information
11:47 EDTGILDOptions with increasing implied volatility
Subscribe for More Information
10:36 EDTGILDGilead volatility increases on wide price movement
Subscribe for More Information
10:18 EDTGILDGilead shares defended at Bernstein
Subscribe for More Information
10:11 EDTGILDGilead slips after VP discusses low-cost Sovaldi for 80 countries
Subscribe for More Information
09:51 EDTGILDGilead drops, trades in wide range
Subscribe for More Information
09:50 EDTGILDGilead down 3.5% after reports of potential generic Sovaldi deal coming
09:49 EDTGILDGilead near deal for generic Sovaldi for developing countries, Bloomberg reports
Subscribe for More Information
09:43 EDTGILDGilead drops 6%, or $6.41, to $100.45
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA YHOO WFM SLW ABX GOOG FB BIDU
September 4, 2014
11:30 EDTGILDStocks with call strike movement; AAL GILD
American Airlines (AAL) November 44 call option implied volatility increased 6% to 39, Gilead (GILD) November 130 call option implied volatility decreased 5% to 40 according to IVolatility.
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
07:21 EDTGILDMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
September 3, 2014
16:01 EDTGILDOptions Update; September 3, 2014
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA TWTR PBR C GILD NFLX FB BIDU
05:51 EDTGILDStocks with implied volatility movement; GILD XLE
Stocks with implied volatility movement; Gilead (GILD) 36, Energy Select Sector SPDR (XLE) 14 according to iVolatility.
1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use